DOGP — what changed in the latest 10-Q
A section-by-section comparison of DOGP's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-19 vs the prior 10-Q · 2026-05-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +10 | −5 | ~1 | 1 |
| Controls & procedures | Text added/removed | +1 | −2 | ~1 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Risk factors, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-19
equipment suppliers; and worldwide political stability and economic growth. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak…
Three Months Ended June 30, 2026 compared with the Three Months Ended June 30, 2025
Revenue for the three months ended June 30, 2026, decreased 13% compared to the three months ended June 30, 2025. Cost of revenues as a percentage of sales decreased 13% between the
periods. The 13% revenue decrease was the result of sustained competitive pressure in the cannabis tele-medicine industry, where intensifying market competition has compressed demand growth through the second quarter of 2026.
Total operating expenses decreased 29% to $217,515 for the three months ended June 30, 2026, compared to $304,892 in Q2 2025. The decrease was driven by a 42% decrease in general and administrative expenses, a 11% decrease in wages and salaries and a 6% decrease in professional fees.
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Three Months Ended March 31, 2026 compared with the Three Months Ended March 31, 2025
Revenue for the three months ended March 31, 2026, increased 5% compared to the three months ended March 31, 2025. Cost of revenues as a percentage of sales decreased 5% between the periods. The 5% revenue increase was achieved despite sustained competitive pressure in the cannabis tele-medicine ind…
Total operating expenses increased 30% to $283,381 for the three months ended March 31, 2026, compared to $218,581 in Q1 2025. The increase was driven by a 140% rise in professional fees and an 18% increase in general and administrative expenses, partially offset by a 7% decline in wages and salarie…
Cash used in operating activities was $13,443 in the three months ended March 31, 2026. We ended the first quarter of 2026 with $19,510 in cash on hand.
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses of $200,470 and $107,36…
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-19
There was no change in our internal control over financial reporting during the quarter ended June 30, 2026, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Text removed vs the prior filing · source: 10-Q · 2026-05-14
direct management oversight of transactions, along with the use of external legal and accounting professionals. As the Company grows, management expects to increase the number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.
There was no change in our internal control over financial reporting during the quarter ended March 31, 2026, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice